CREDAI's Super Chennai initiative launches website to showcase city's global potential
Conceptualised to celebrate Chennai's strengths and promote its potential in diverse sectors, the website will showcase the city's identity and help people connect for opportunities, explore the vibrant landscape, and find real-time city updates. This will be the digital platform of 'Super Chennai', a movement that aims to position Chennai as one of the liveable and thriving global cities. It was launched by Confederation of Real Estate Developers' Associations of India (CREDAI) earlier this year.
Ranjeeth D. Rathod, managing director (MD), Super Chennai, said the website would enable citizens to explore Chennai under five key elements — 'Live, Visit, Work, Invest, and Innovate'. While targeting the Gen Z population, the website, which is part of the larger movement, will be a comprehensive storehouse of trends, opportunities, and events.
A campaign on 'Super Chennai' will begin on July 21, 2025, with a mix of outreach activities, including social media events, television, and hoardings. The initiative is open to collaborations with government agencies and various institutions, start-ups, and corporates to showcase Chennai as a vibrant hub, Mr. Rathod added.
Elaborating on the initiative, A. Mohamed Ali, president, CREDAI Chennai, said the campaign would present the best of Chennai, be it art, technology, entrepreneurship, or healthcare, to the world and accelerate these developments with community participation.
'Super Chennai' also announced its partnership with Pointcast, a United States-based company. Aditya Swaminathan, founding team member, Pointcast, said the technology combined geolocation with gestures for a search tool wherein users could point their mobile phone at a location to get real-time updates. Residents can also suggest new points of interest in Chennai through the soon-to-be-launched mobile application.
C.K. Kumaravel, co-founder, Naturals Salon and Spa, was presented with 'Super Chennai Icon of the Month' award at the event for his contribution towards women's entrepreneurship and inclusive growth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
AU Bank profit rises 16% to 581 cr in Apr-June qtr
Jaipur: AU Small Finance Bank posted a 16% growth in net profit to Rs 581 crore during the first quarter of this financial year. The Jaipur-based bank had earned a net profit of Rs 503 crore in the same quarter of the previous fiscal year. Tired of too many ads? go ad free now The total income rose to Rs 5,189 crore during the June 2025 quarter from Rs 4,278 crore in the same period of FY25, AU Small Finance Bank said in a regulatory filing. Interest earned by the bank improved to Rs 4,378 crore compared to Rs 3,769 crore in the June quarter of FY25. Net interest income rose to Rs 2,045 crore during the quarter against Rs 1,921 crore a year ago. The bank's operating profit also increased to Rs 1,312 crore from Rs 952 crore in the year-ago period. Gross loan portfolio (GLP) grew 18% to Rs 1,17,624 crore compared to Rs 99,792 crore as of Q1 FY25, it said. Similarly, net NPAs, or bad loans, increased to 0.88% against 0.63% in the year-ago period. As a result, provisions and contingencies almost doubled to Rs 533 crore during the first quarter compared to Rs 283 crore a year ago. Provision Coverage Ratio (PCR) stood at 83% at the end of June 2025. However, the capital adequacy ratio of the bank declined to 19.42 per cent from 20.11 per cent in the same quarter of FY25. Commenting on quarterly numbers, AU Small Finance Bank MD and CEO Sanjay Agarwal said, "We have reported another set of consistent performance in a seasonally soft quarter, showing sustainable growth in deposits, assets, and profitability". As the economic cycle strengthens, AU is well-positioned to navigate near-term uncertainties while staying committed to the long-term vision of building a forever bank that can truly scale with sustainability,headded.
Time of India
3 hours ago
- Time of India
Zydus Life's plans for cancer biosimilar hit a legal hurdle
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: The Delhi High Court has issued an interim injunction against Ahmedabad-based drug maker Zydus Lifesciences after a case filed by the US pharma giant Bristol Myers Squibb alleging patent infringement on its blockbuster anticancer drug Opdyta nivolumab ) branded as Opdivo in other restraining order comes as a setback for the Indian drug maker which was running clinical trials in India for the launch of the biosimilar versions of nivolumab. The earliest patent for the drug expires in India on May 2, 2026. The next hearing for the case is August 101-page order issued on July 18 by Justice Mini Pushkarna ruled that the defendants, and all others acting on its behalf, are restrained from manufacturing, using, selling, offering for sale, importing, exporting, advertising, or dealing in any biosimilar/similar biologic of nivolumab, the suit patent, during the pendency of the present suit. The order stated the plaintiffs shall suffer irreparable loss, in case the interim relief as prayed for, was not injections are one of the many latest generation immunotherapy drugs also known as checkpoint inhibitors increasingly used to treat several types of cancers including skin, lungs, kidneys, and Hodgkin lymphoma. It works by activating the body's T-cells or immune cells by targeting a protein called PD-1, thereby unleashing an attack on the cancer vials are sold in India for roughly '2 lakh but for patients who are part of the company's assistance or access programs, the drug is available at a slab-wise discounted the India data is not available, globally Bristol Myers Squibb recorded Opdivo sales of $9.3 billion in 2024. Indian companies have launched biosimilars at half the cost of those charged by their global in Indian patent laws told ET that the court has taken a view that stockpiling of a product during its active patent life amounts to infringement and to release it or flood the market is not legally valid."This opinion may have implications for the other ongoing disputes like the weight-loss drug semaglutide (branded Wegovy) case between Novo Nordisk and Dr. Reddy's Labs or Roche versus Natco for Risdiplam (drug used for a rare disease called spinal muscular atrophy or SMA) case," a senior lawyer petition from BMS noted that Zydus Lifesciences was conducting clinical trials for nivolumab and on its investigation found that the company had plans to launch it during the patent period. The Indian company, it said, had applied for a marketing approval with the central drug regulatory its part, lawyers on behalf of Zydus defended saying its product ZRC-3276 does not infringe upon the existing patents and is following the regulatory was represented by a battery of top lawyers including Harish Salve, Dushyant Dave, and Rajiv Nayar, while Squibb & Sons was represented by Sandeep Sethi, PS Raman, Amit Sibal and Pravin Anand, among others.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Green light for HFT firm Jane Street to re-enter domestic markets
But bourses to closely monitor company's future dealings on ongoing basis Samie Modak Khushboo Tiwari Mumbai Listen to This Article High-frequency trading (HFT) firm Jane Street has been allowed to re-enter the domestic markets after it fulfilled the Securities and Exchange Board of India's (Sebi's) direction to deposit alleged 'unlawful gains' of ₹4,844 crore in an escrow account before July 14. According to sources, Sebi last week informed Jane Street via email that the ban imposed on the New York-based trading firm had been lifted. 'The July 3 interim order clearly states that upon deposit compliance, the restriction on accessing the securities market will cease to apply. However, this has been formally communicated to Jane Street by Sebi through an
